SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that its presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference will be webcast live on November 5 at 12:40 p.m. Eastern Time. Vical's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies, development programs, and strategic partnerships. The webcast will be available live and archived for 90 days through the events page at http://www.vical.com.
The company's presentations at the BIOCOM Investor Conference (San Diego, October 31 - November 2) and at the Lazard Capital Markets Annual Life Sciences Conference (New York, November 27 - 28) will not be webcast.
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
Contacts: Investors: Media:
Alan R. Engbring Susan Neath
Vical Incorporated Porter Novelli Life Sciences
(858) 646-1127 (619) 849-6007
|SOURCE Vical Incorporated|
Copyright©2007 PR Newswire.
All rights reserved